tbuckley/cabot-search huggingface dataset:
AB0435 Clinical features of ra patients with or without remission states of ACR/EULAR and modified health assessment questionnaire (MHAQ):
Authors: S. Nishiyama, K. Ohashi, T. Aita, Y. Yoshinaga, S. Miyawaki, S. Tohma
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To compare clinical features in patients with RA classified by ACR/EULAR (A/E) remission and mHAQ≤0.5, and to explore clinical factors for reaching or maintaining the remission. <h3>Methods</h3> Data of 831 patients receiving MTX monotherapy for a continuous period of 3 years from 2008 were extracted from <i>Ninja</i> 2010, an annually updated nationwide database in Japan. The patients were divided into four groups according to their remission states, both A/E and HAQ remission (A), only A/E remission (B), only HAQ remission (C) and neither A/E nor HAQ remission (D). Total joint index (TJI) was calculated as the sum of tender and swollen joint counts divided by the number of evaluable joints in the region of interest (1). <h3>Results</h3> Clinical features of the 4 groups were different (table 1). SDAI was different in each groups whereas DAS28 did not differ between the group A and B, and between the group C and D. The majority of patients remained in their groups throughout the period, and a transition between the group A and C occurred in around 20% of patients. Patients remained in the group A for at least 2 years had higher rate of mHAQ=0 and lower levels of physician global assessment and SDAI than patients moved from the group A to C. Patients moved from the group C to A had low levels of pain VAS, patient global assessment, physician global assessment, DAS28, and SDAI and possessed low rate of TJI&gt;0 in upper/large and upper/small regions compared to patients remained in the group C for at least 2 years. <h3>Conclusions</h3> Clinical features were different between the 4 groups classified according to A/E and HAQ remission states. Patients that achieved and/or maintained both A/E and HAQ remission shared common features of low levels of physician global assessment and SDAI. <h3>References</h3> Nishiyama S, et al, Proposing a method of regional assessment and a novel outcome measure in rheumatoid arthritis. Rheumatol Int. DOI 10.1007/s00296-011-2058-9, 2011 <h3>Disclosure of Interest</h3> None Declared
Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases
Authors: CP Leith, IM Chen, KJ Kopecky, FR Appelbaum, DR Head, JE Godwin, JK Weick, CL Willman
Journal: Blood (1995)
BIM phosphorylation enhances its pro-apoptotic activity through down-regulation of the interaction with MCL-1
Authors: Jianghua Lu, Bonnie Quearry, Hisashi Harada
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

4071 

BIM, a pro-apoptotic “BH3-only” member of the BCL-2 family, is required for apoptosis induced by chemotherapeutic drugs (i.e. Taxol, dexamethasone, and Gleevec). For instance, BIM down-regulation by gene-targeting or small interfering RNA (siRNA) shows strong resistance to treatment with these drugs. This indicates that BIM could be a key regulator in anticancer therapy against human malignancies. In this study, we focus on the post-translational modification of BIM and its effect with other BCL-2 family members. We used HeLa cells to study the precise mechanisms of BIM-mediated apoptosis by Taxol treatment. Down regulation of BIM by siRNA improves cell viability, confirming its importance. Taxol treatment results in phosphorylation of BIM prior to the onset of apoptosis. Using pharmacological inhibitors, inhibition of Jun N-terminal kinase (JNK) prevents BIM phosphorylation and reduces apoptosis, but the inhibition of extracellular signal-regulated kinase, p38-mitogen activated protein kinase or phosphoinositide 3-kinase has no effect. Transient expression of non-phosphorylatable mutations (Ser100, Thr112 and Ser114) eradicates the phosphorylation-specific BIM band-shift on SDS-PAGE. Most importantly, non-phosphorylatable mutations significantly curtail taxol-induced apoptosis. After Taxol treatment, the BIM/ anti-apoptotic protein MCL-1 interaction is dramatically decreased and the BIM/ multi-domain pro-apoptotic effector Bax interaction is increased, although the localization and overall protein expression levels of these proteins are constant. In contrast, a non-phosphorylatable BIM mutant treated by Taxol does not show significant change of the interaction with MCL-1 and Bax. These results demonstrate that phosphorylation of BIM is required for down-regulating the interaction with MCL-1 and up-regulating the interaction with Bax, and this regulation enhances the pro-apoptotic activity of BIM. The mechanisms of Taxol-induced BIM phosphorylation and the interaction with other Bcl-2 family members provide new insights into BIM regulation and function.
OP0119 Great progress but much more needed: Hospitalizations due to complicated gastric and duodenal ulcers in the US (1990-2009)
Authors: G. Singh, A. Mannalithara, A. Mithal, G. Triadafilopoulos
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Gastrointestinal bleeding, perforation, and obstruction of gastric (GU) and duodenal ulcers (DU) (collectively Peptic Ulcer Disease, PUD) are significant causes of hospitalizations and mortality in the US. <h3>Objectives</h3> To examine hospitalizations due to complicated GUs and DUs over 20 years and correlate them to introduction of anti-<i>H pylori</i> eradication strategies and changes in the use of NSAIDs and COX-2 specific inhibitors in the US. <h3>Methods</h3> The Nationwide Inpatient Sample (NIS) is a stratified random sample of US community hospitals, with detailed information on all hospitalizations, regardless of payer<sup>1</sup>. We studied hospitalizations from 1990-2009 with a primary diagnosis of complicated ulcers (GU, DU, PUD) and analyzed them as a proportion of total all-cause hospitalizations. <h3>Results</h3> From 1990 to 2009 there were 732.2 million hospitalizations in the US. Of these, 2.8 million (0.38%) were for a complicated GU, DU, or PUD. All-cause hospitalizations increased from 34.9 million in 1990 to 39.4 million in 2009, probably reflecting the growth of the aging population. However, hospitalizations for complicated GU, DU and PUD declined from 163,544 in 1990 to 100,589 in 2009 (see Figure). The decline started in 1995, following the NIH consensus conference in 1994 recommending <i>H. pylori</i> eradication and continued through the introduction of coxibs in 1999, and then the withdrawal of 2 coxibs in 2004-5. Complicated PUD hospitalizations transiently increased in 2005, but then resumed their steady decline in recent years even as Cox-2 specific inhibitor prescriptions continued to decrease. <h3>Conclusions</h3> National population data strongly suggest that the introduction of <i>H. pylori</i> eradication therapy triggered a trend towards fewer hospitalizations for complicated ulcer disease in the US. The continuing decline in hospitalizations may reflect better physician and patient education and increasing use of gastroprotective therapies. Nevertheless, the number of PUD hospitalizations in 2009 still remains disturbingly high (&gt;100,000) and calls for continuous education on safer NSAID prescribing, gastroprotection and vigilance. <h3>References</h3> [1]HCUP Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2007-2009. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/nisoverview.jsp <h3>Disclosure of Interest</h3> G. Singh Grant/Research support from: Horizon Pharma, Pfizer, Astra-Zeneca, Pozen, Sunovion, Consultant for: Pfizer (no personal compensation), A. Mannalithara: None Declared, A. Mithal: None Declared, G. Triadafilopoulos: None Declared
IMPACT ON TWO-YEAR OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION COMPLEXITY AND PLATELET REACTIVITY AMONG PATIENTS WITH STABLE CORONARY ARTERY DISEASE: INSIGHT FROM THE ADAPT-DES STUDY
Authors: Philippe Genereux, Ajay Kirtane, Tullio Palmerini, Bernhard Witzenbichler, Mayank Yadav, Giora Weisz, Thomas Stuckey, Dominic Francese, Ke Xu, Akiko Maehara, Roxana Mehran, Gregg Stone
Journal: Journal of the American College of Cardiology (2015)
Respiratory Syncytial Virus and Parainfluenza Virus
Authors: Caroline Breese Hall
Journal: New England Journal of Medicine (2001)

Respiratory syncytial virus (RSV), originally recovered from a colony of chimpanzees with coryza and designated chimpanzee coryza agent,1,2 and human parainfluenza virus types 1, 2, 3, and 4 have been known primarily as respiratory pathogens in young children. They are now recognized as important pathogens in adults as well. Adults infected with these viruses tend to have more variable and less distinctive clinical findings than children, and the viral cause of the infection is often unsuspected. The consistency of the annual outbreaks of these agents and the frequency of reinfection suggest that they impose a considerable, but ill-defined, disease . . .
CIRUGÍA ENDOSCÓPICA ENDOLUMINAL HÍBRIDA ASISTIDA POR LAPAROSCOPIA: EXPERIENCIA DE UN CENTRO TERCIARIO
Authors: G Fernández-Esparrach, H Córdova, C Rodríguez de Miguel, JM Bordas, À Ginès, M Pellisé, O Sendino, A Cárdenas, M Aceituno, B González-Suárez, R Bravo, D Momblán, A Lacy, J Llach
Journal: Endoscopy (2010)

Introducción: la endoscopia terapéutica tiene una serie de limitaciones determinadas por las características flexibles del endoscopio y la falta de triangulación. La combinación de endoscopia y laparoscopia es una alternativa que permite el tratamiento de lesiones de mayor tamaño de forma mínimamente invasiva.
Case 28-1993
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Leonard C. Marcus, Anthony R. Mattia
Journal: New England Journal of Medicine (1993)

Presentation of CaseA 63-year-old man was admitted to the hospital because of fever, chills, and fatigue.The patient had been in stable health until 17 days earlier, when he experienced the onset of dull occipital headache, myalgias, and night sweats. He used analgesic medications intermittently, with transient improvement in his symptoms, but did not check his temperature during the first two weeks of the illness. The myalgias disappeared after two weeks. During the third week of symptoms the patient found that his temperature became elevated, usually at night, and rose as high as 39.3 °C; he also observed that . . .
P708Homocysteine induces apoptosis of arterial smooth muscle cells via NOX4-produced reactive oxygen
Authors: E N Ter Horst, NE Hahn, JA Sipkens, VWM Van Hinsbergh, RJP Musters, YM Smulders, EC Eringa, KK Griendling, HWM Niessen, PAJ Krijnen
Journal: Cardiovascular Research (2014)

Introduction: Elevated levels of homocysteine (Hcy) form a vascular risk factor and can induce apoptosis of endothelial cells and vascular smooth muscle cells. Recent studies have shown that NADPH oxidase (NOX)-mediated reactive oxygen species (ROS) play a role in Hcy-induced apoptosis of endothelial cells. In this study we have analyzed the effect of Hcy on the different NOX isoforms and their role in human arterial smooth muscle cells (SMCs). Methods: Human arterial SMCs isolated from the human umbilical cord were incubated with 100 μM Hcy for 24 hours and were analyzed for cell viability by determining phosphatidylserine exposure via Flow cytometry and caspase 3 activity measurements. With use of digital imaging microscopy, expression of NOX1, 2 and 4 and production of ROS were studied. NOX4 small interference RNA (siRNA) were used to specify the role of NOX4 in Hcy-induced apoptosis. Results: Hcy induced a significant increase in phosphatidylserine exposure and caspase 3 activity in arterial SMC. This was accompanied by a significant translocation of NOX4 from the cytoplasm to (peri)nuclear regions, coinciding with a significant increase in local ROS production. Hcy did not affect expression levels, nor subcellular localization of NOX1 and NOX2. Knock-down of NOX4 using siRNA significantly reduced Hcy-induced (peri)nuclear NOX4 expression, concomitant ROS production and apoptosis in isolated arterial SMCs. Conclusion: Pathophysiological concentrations of Hcy induce apoptosis of human arterial SMCs via NOX4 mediated ROS production.
Abstract P1-11-18: Neoadjuvant Use of 5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC) Followed by Docetaxel (T) with Concurrent COX-2 Inhibitor in Women with Stage II/III Breast Cancer: A Sub-Analysis of Cardiac Function
Authors: LWC Chow, AYS Yip, RHW Chan, Y-M Lam, M. Toi
Journal: Cancer Research (2010)

Abstract BACKGROUND: Anthracycline and taxane have been widely used and studied in neoadjuvant setting for treatment of locally advanced breast cancer. Although addition of COX-2 inhibitors might enhance the anticancer effect of chemotherapy, many studies were halted with the concern of possible cardiotoxicity. This sub-study is to evaluate the change in cardiac function of patients during treatment with pre-operative FEC-T with concurrent celecoxib until and after surgery. METHODS: A group of 47 patients, age ranged from 33 to 58 years (mean age 46±6 years), who received four cycles of 3-weekly FEC followed by four cycles of 3-weekly T with concurrent oral celecoxib before surgery (F: 500mg/m2; E: 100mg/m2; C: 500mg/m2; T: 100mg/m2; Celecoxib: 200mg bid), were studied. Echocardiography was performed at baseline, after 4 cycles of FEC and after 4 cycles of T before surgery, and 6 months, 12 months and 18 months after surgery to evaluate changes in left ventricular ejection fraction (LVEF) across time-points. Paired sample statistics was conducted. RESULTS: Patients tolerated well with this regimen. Neither life-threatening toxicity nor clinical symptom of cardiac toxicity was observed. Of 47 evaluable cases, LVEF was assessed in 47 patients pre-operatively and in 32 patients post-operatively. During concurrent celecoxib treatment, the mean LVEF increased from 68.5%±6.6% at baseline to 72.3%±3.6% after FEC and to 73.0%±4.1% after T. When compared to baseline, the changes were statistically significant after FEC (p=0.002) and after T (P&amp;lt;0.0001) in 47 patients. LVEF however did not change at 6 months (72.8%±3.8%), 12 months (72.7%±3.1%) and 18 months (72.4%±3.3%) after surgery in 32 patients. The remaining 15 patients are still under follow up for cardiotoxicity until 1 year after surgery. CONLCUSIONS: Neoadjuvant FEC-T with concurrent celecoxib is well-tolerated. The short-term treatment increased LVEF during the course of neoadjuvant chemotherapy and remains good LVEF after surgery. This is an interesting finding which warrants further investigation of the possible protective effect on cardiac function. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-11-18.
Trifurcated hepatic duct with low union complicated by choledocholithiasis
Authors: J. Yang, K. Kim, T. Kim
Journal: Endoscopy (2013)

A 74-year-old man was admitted to our hospital with right upper quadrant pain. Laboratory data on admission were as follows: aspartate transaminase (AST) 26 IU/L, alanine transaminase (ALT) 70 IU/L, total bilirubin 0.9 mg/dL, alkaline phosphatase 337 U/L, and γ-glutamyl transpeptidase 552 U/L. Magnetic resonance cholangiopancreatography (MRCP) revealed a trifurcated configuration of hepatic ducts with an unusual low union, and drainage of the cystic duct into the right posterior segmental duct, accompanied by several common bile duct (CBD) stones ([Fig. 1]). Endoscopic retrograde cholangiopancreatography (ERCP) revealed similar findings to those of the MRCP. The CBD stones were removed successfully using a retrieval basket after endoscopic sphincterotomy ([Fig. 2]). After 4 days, the patient underwent cholecystectomy followed by hepaticojejunostomy.
GENDER DIFFERENCES IN RISK PROFILES AND MANAGEMENT OF PATIENTS WITH HEART FAILURE REHOSPITALIZATIONS: OBSERVATIONS FROM THE GULF CARE STUDY
Authors: Amar Salam, Kadhim Sulaiman, Jassim Al Suwaidi, Nidal Asaad, Khalid AlHabib, Wael Almahmeed, Alawi Alsheikh-Ali, Ahmed AL-Motarreb, Prashanth Panduranga, Hussam AlFaleh, Abdulfatah Elasfar, Nooshin Bazargani, Mohammad Al Jarallah, Haitham Amin, Mustafa Ridha, Awad Alqahtani, Rajvir Singh, Robert Bonow, Magdi Yacoub
Journal: Journal of the American College of Cardiology (2015)
Case 34-2014
Authors: Ronald L. Thibert, Ann-Christine Duhaime, Paul A. Caruso, Anat Stemmer-Rachamimov
Journal: New England Journal of Medicine (2014)

A 7-year-old boy was evaluated because of focal seizures, twitching of the right arm and the right side of the face, and progressive weakness. Imaging revealed progressive left cortical atrophy and a focal lesion in the left parietal cortex. A diagnostic procedure was performed.
Diltiazem and Reinfarction in Patients with Non-Q-Wave Myocardial Infarction
Authors: Robert S. Gibson, William E. Boden, Pierre Theroux, Hans D. Strauss, Craig M. Pratt, Mihai Gheorghiade, Robert J. Capone, Michael H. Crawford, Robert C. Schlant, Robert E. Kleiger, Phillip M. Young, Kenneth Schechtman, M. Benjamin Perryman, Robert Roberts
Journal: New England Journal of Medicine (1986)

We performed a multicenter, double-blind, randomized study to evaluate the effect of diltiazem on reinfarction after a non-Q-wave myocardial infarction. Nine centers enrolled 576 patients: 287 received diltiazem (90 mg every six hours) and 289 received placebo. Treatment was initiated 24 to 72 hours after the onset of infarction and continued for up to 14 days. The primary end point, reinfarction, was defined as an abnormal reelevation of MB creatine kinase in plasma within 14 days. Reinfarction occurred in 27 patients in the placebo group (9.3 percent) and in 15 in the diltiazem group (5.2 percent)--a 51.2 percent reduction in cumulative life-table incidence (P = 0.0297; 90 percent confidence interval, 7 to 67 percent). Diltiazem reduced the frequency of refractory postinfarction angina (a secondary end point) by 49.7 percent (P = 0.0345; 90 percent confidence interval, 6 to 73 percent). Mortality was similar in the two groups (3.1 and 3.8 percent, respectively, in the placebo and diltiazem groups), but adverse drug reactions (most of which were mild) were more common in the diltiazem group. Nevertheless, the drug was well tolerated, despite concurrent treatment with beta-blockers in 61 percent of the patients. We conclude that diltiazem was effective in preventing early reinfarction and severe angina after non-Q-wave infarction and that it was also safe and generally well tolerated.
Abstract 2373: The LCBRN: a biospecimen resource for lung cancer biomarker and discovery science.
Authors: Christopher A. Moskaluk
Journal: Cancer Research (2013)

Abstract The Lung Cancer Biospecimen Resource Network (LCBRN) is an open access biorepository that obtains specimens from lung cancer patients (tissue, blood, urine, bronchial lavage fluid and saliva) and makes them available to biomedical researchers. Specimen collection is supported at 3 collection sites (Medical University of South Carolina, The University of Virginia, and Washington University at St. Louis) in compliance with uniform standard operating procedures. The specimens are annotated with clinical, radiologic and pathologic data. Histologic and molecular quality control procedures are in place for tissue samples. Lung cancer and non-neoplastic lung tissue aliquots are processed into DNA, RNA and protein fractions, which are also available. Fluid biosamples are available from subjects prior to, and after surgery to remove the cancer. A cohort of subjects are followed for recurrence with serial biofluid sampling. Specimens are currently available from over 300 research subjects. The application form for biospecimens and additional information is available at http://LCBRN.org. Citation Format: Christopher A. Moskaluk. The LCBRN: a biospecimen resource for lung cancer biomarker and discovery science. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2373. doi:10.1158/1538-7445.AM2013-2373
434 FIBROSIS PROGRESSION IN INACTIVE HEPATITIS B VIRUS CARRIERS: A LONGITUDINAL STUDY WITH PAIRED LIVER STIFFNESS MEASUREMENTS
Authors: V.W.-S. Wong, G.L.-H. Wong, Z. Yu, S.H.-T. Chu, H.-Y. Chan, C.-H. Tse, H.L.-Y. Chan
Journal: Journal of Hepatology (2013)
AB0100 Identification of the antimicrobial peptide LL-37 as a potential mediator of synovial inflammation in RA
Authors: P. Neregård, M. Engström, M. Lindh, B. Agerberth, A.I. Catrina
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> LL-37, a member of the cathelicidin family of host defense peptides, has a broad range of antimicrobial and immunomodulatory effects that potentially can have an impact on the regulation of the adaptive immune system. <h3>Objectives</h3> In this study we aimed to investigate a potential role for LL-37 in mediating chronic synovial inflammation. <h3>Methods</h3> 49 patients meeting the 1987 American College of Rheumatology (ACR) criteria for RA were recruited for this study. We evaluated LL-37 by immunohistochemistry in synovial biopsy samples obtained before and after a mean of 8 weeks of treatment from 15 patients treated with adalimumab, 12 patients treated with etanercept and 11 patients treated with methotrexate, as well as from 11 patients prior to and 2 weeks after injection with intraarticular glucocorticoids. LL-37 was also evaluated in synovial biopsies obtained from 10 healthy volunteers. Microscopic results were analyzed by double-blind semi-quantitative analysis. Synovial localization of LL-37 was performed by double fluorescent stainings for LL-37 and cell surface markers. LL-37 was detected in synovial fluid by Western blots. Statistical analysis was performed using Wilcoxon test for paired comparisons and Man-Whitney test for comparisons of independent samples. <h3>Results</h3> LL-37 was expressed in most of the RA synovial biopsies both in the lining and sublining layers and readily identified in the synovial fluid. Serial and double-fluorescent immunostaining for cell surface markers identifies granulocytes (CD66 positive cells) and macrophages (CD163 positive cells) as main cells expressing LL-37. Inflamed synovial tissue obtained from active arthritis prior to treatment expressed higher levels of LL-37 as compared to healthy individuals. Treatment with adalimumab, etanercept and intraarticular glucocorticoids but not methotrexate resulted in a significant down-modulation of LL-37 expression. <h3>Conclusions</h3> Our results demonstrate presence of LL-37 in the context of chronic synovial inflammation and show specific regulation of this molecule by distinct anti-rheumatic agents. Further investigation to reveal the functional consequences of our findings on synovial antimicrobial and inflammatory activity is needed. <h3>Disclosure of Interest</h3> None Declared
Case 2-2010
Authors: Eric M. Isselbacher, Seth J. Kligerman, Kaitlyn M. Lam, Rocio M. Hurtado
Journal: New England Journal of Medicine (2010)

A 47-year-old man was admitted to this hospital because of abdominal pain of 5 weeks' duration, which radiated to the flank. He had had intermittent abdominal pain and constipation for 15 years. He was born in Central America and lived in rural and urban areas until immigrating to the United States more than 25 years before admission. Computed tomography of the abdomen revealed renal abnormalities consistent with infarcts. Echocardiography revealed a left ventricular aneurysm with thrombus. A diagnostic test was performed.